{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lasofoxifene",
    "query": {
      "intervention": "Lasofoxifene"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T11:59:41.218Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05696626",
      "title": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lasofoxifene in combination with abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant in combination with abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LeonaBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2023-10-31",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-09-02T11:59:41.218Z",
      "location_count": 36,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Santa Rosa, California + 25 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05696626"
    },
    {
      "nct_id": "NCT00163137",
      "title": "Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "raloxifene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ligand Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "48 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "48 Years to 75 Years · Female only"
      },
      "enrollment_count": 540,
      "start_date": "2003-05",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2011-08-12",
      "last_synced_at": "2026-09-02T11:59:41.218Z",
      "location_count": 72,
      "location_summary": "Albany, California • Berkeley, California • La Jolla, California + 49 more",
      "locations": [
        {
          "city": "Albany",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00163137"
    },
    {
      "nct_id": "NCT06197568",
      "title": "Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vulvo Vaginal Atrophy (VVA)"
      ],
      "interventions": [
        {
          "name": "Lasofoxifene Tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azure Biotech Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 60 Years · Female only"
      },
      "enrollment_count": 90,
      "start_date": "2026-06-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-02T11:59:41.218Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06197568"
    },
    {
      "nct_id": "NCT01042379",
      "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Breast Tumors",
        "Angiosarcoma",
        "TNBC - Triple-Negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Hormone Receptor Negative Tumor",
        "Early-stage Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 479 (Ganitumab) plus Metformin",
          "type": "DRUG"
        },
        {
          "name": "MK-2206 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "T-DM1 and Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        },
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "PLX3397",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 4 cycle",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib plus Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Patritumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 8 cycle",
          "type": "DRUG"
        },
        {
          "name": "SGN-LIV1A",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab plus Olaparib",
          "type": "DRUG"
        },
        {
          "name": "SD-101 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib plus trastuzumab and pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab plus REGN3767",
          "type": "DRUG"
        },
        {
          "name": "Trilaciclib with or without trastuzumab + pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "SYD985 ([vic-]trastuzumab duocarmazine)",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARX788",
          "type": "DRUG"
        },
        {
          "name": "ARX788 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "VV1 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Zanidatamab",
          "type": "DRUG"
        },
        {
          "name": "Lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "Z-endoxifen",
          "type": "DRUG"
        },
        {
          "name": "ARV-471",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Endoxifen + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig + TDXd",
          "type": "DRUG"
        },
        {
          "name": "Dan222 + Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab + Cemiplimab + Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584 + Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab (20mg/kg Q3W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2010-03-01",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-02T11:59:41.218Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042379"
    },
    {
      "nct_id": "NCT00141323",
      "title": "Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ligand Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 80 Years · Female only"
      },
      "enrollment_count": 8556,
      "start_date": "2001-11",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2011-08-15",
      "last_synced_at": "2026-09-02T11:59:41.218Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Palm Desert, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141323"
    },
    {
      "nct_id": "NCT03781063",
      "title": "Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sermonix Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2019-09-20",
      "completion_date": "2025-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-02T11:59:41.218Z",
      "location_count": 42,
      "location_summary": "Phoenix, Arizona • Yuma, Arizona • Duarte, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03781063"
    },
    {
      "nct_id": "NCT04432454",
      "title": "Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lasofoxifene and abemaciclib (VERZENIO (R)).",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sermonix Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2020-09-29",
      "completion_date": "2025-01-28",
      "has_results": false,
      "last_update_posted_date": "2025-02-13",
      "last_synced_at": "2026-09-02T11:59:41.218Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Yuma, Arizona • Fountain Valley, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432454"
    }
  ]
}